SUBCUTANEOUS ADMINISTRATION OF INTERLEUKIN-2 AND INTERFERON-ALPHA-2B IN ADVANCED RENAL-CELL CARCINOMA - A CONFIRMATORY STUDY

被引:20
|
作者
FACENDOLA, G
LOCATELLI, MC
PIZZOCARO, G
PIVA, L
PEGORARO, C
PALLAVICINI, EB
SIGNAROLDI, A
MEREGALLI, M
LOMBARDI, F
BERETTA, GD
SCANZI, F
LABIANCA, R
LUPORINI, G
机构
[1] OSPED S CARLO BORROMEO,DIV MED ONCOL,I-20153 MILAN,ITALY
[2] IST NAZL TUMORI,DIV ONCOL CHIRURG UROL,I-20133 MILAN,ITALY
[3] OSPED CARLO POMA,DIV UROL,MANTOVA,ITALY
[4] OSPED MAGGIORE CREMA,DIV MED,CREMA,ITALY
[5] OSPED SANTA CORONA,DIV MED 2,GARBAGNATE,ITALY
[6] DIV MED ONCOL,MAGENTA,ITALY
[7] OSPED E BASSINI,MED ONCOL SERV,DIV MED,CINISELLO BASLSAMO,ITALY
[8] OSPED MAGGIORE NIGUARDA,DIV MED ONCOL,MILAN,ITALY
关键词
ADVANCED RENAL CANCER; INTERLEUKIN; 2; INTERFERON ALPHA; SUBCUTANEOUS ADMINISTRATION;
D O I
10.1038/bjc.1995.542
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent clinical studies have suggested that the combination of subcutaneous recombinant human interleukin 2 (rIL-2) and interferon alpha (rIFN-alpha) is especially promising in advanced renal cell carcinoma. We assessed the safety, activity and toxicity of home therapy with these two agents in 50 patients. Each treatment cycle consisted of a 2 day pulse phase, with 9 X 10(6) IU m(-2) of rIL-2 being given subcutaneously every 12 h, followed by a 6 week maintenance phase during which rIL-2 1.8 X 10(6) IU m(-2) was administered subcutaneously every 12 h on days 1-5 and rIFN-alpha 2b 5 X 10(6) IU m(-2) once a day on days 1, 3 and 5. Objective responses (CR + PR) occurred in 9/50 (18%) patients, six of whom (12%) achieved a complete response. Disease stabilisation was observed in 17 cases (34%) and 18 patients progressed during therapy. In the other six cases, treatment was interrupted early for toxicity or patient refusal. One patient died of myocardial infarction during the second cycle. The overall median survival was 12 months. Home therapy with subcutaneous rIL-2 + rIFN-alpha 2b proved to be active, feasible and moderately toxic, but serious adverse events can sometimes occur.
引用
收藏
页码:1531 / 1535
页数:5
相关论文
共 50 条
  • [1] SEQUENTIAL TREATMENT OF PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA WITH AUTOLOGOUS TUMOR VACCINE AND SUBCUTANEOUS ADMINISTRATION OF RECOMBINANT INTERLEUKIN-2 AND INTERFERON-ALPHA-2B
    POMER, S
    THIELE, R
    DANIEL, V
    WEIMER, R
    LOHRKE, H
    SCHIRRMACHER, V
    STAEHLER, G
    WORLD JOURNAL OF UROLOGY, 1991, 9 (04) : 223 - 227
  • [2] RENAL-CELL CARCINOMA WITH SUBCUTANEOUS INJECTIONS OF INTERLEUKIN-2 AND INTERFERON-ALPHA
    HOFMOCKEL, G
    THEISS, M
    BUSSEN, D
    WIRTH, MP
    FROHMULLER, HGW
    UROLOGE-AUSGABE A, 1994, 33 (05): : 434 - 439
  • [3] DO BONE METASTASES OF RENAL-CELL CARCINOMA RESPOND TO IMMUNOTHERAPY WITH INTERLEUKIN-2 AND INTERFERON-ALPHA-2B
    METZNER, B
    SIEGMUND, R
    KIRCHNER, H
    ATZPODIEN, J
    ILLIGER, HJ
    TUMORDIAGNOSTIK & THERAPIE, 1991, 12 (05) : 192 - 196
  • [4] INTERLEUKIN-2 AND INTERFERON IN RENAL-CELL CARCINOMA
    WERSALL, P
    MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY, 1993, 10 (1-2): : 71 - 76
  • [5] A COMBINATION OF SUBCUTANEOUS RECOMBINANT INTERLEUKIN-2 AND RECOMBINANT INTERFERON-ALPHA IN THE TREATMENT OF ADVANCED RENAL-CELL CARCINOMA OR MELANOMA
    VUORISTO, M
    JANTUNEN, I
    PYRHONEN, S
    MUHONEN, T
    KELLOKUMPULEHTINEN, P
    EUROPEAN JOURNAL OF CANCER, 1994, 30A (04) : 530 - 532
  • [6] TREATMENT OF PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA WITH SUBCUTANEOUS RECOMBINANT INTERFERON-ALPHA-2B AND CONTINUOUS-INFUSION OF RECOMBINANT INTERLEUKIN-2 - A PHASE-II STUDY
    MORANT, R
    RICHNER, J
    AAPRO, M
    PALMER, PA
    SENN, HJ
    ONKOLOGIE, 1994, 17 (03): : 254 - 260
  • [7] IMMUNOTHERAPY OF ADVANCED RENAL-CELL CANCER USING SUBCUTANEOUS RECOMBINANT INTERLEUKIN-2 AND INTERFERON-ALPHA
    KIRCHNER, H
    DERIESE, W
    ALLHOFF, E
    POLIWODA, H
    ATZPODIEN, J
    WORLD JOURNAL OF UROLOGY, 1991, 9 (04) : 219 - 222
  • [8] CONTINUOUS INTRAVENOUS INTERLEUKIN-2 INFUSION AND SUBCUTANEOUS INTERFERON-ALPHA IN METASTATIC RENAL-CELL CARCINOMA
    FOSSA, SD
    AUNE, H
    BAGGERUD, E
    GRANERUD, T
    HEILO, A
    THEODORSEN, L
    EUROPEAN JOURNAL OF CANCER, 1993, 29A (09) : 1313 - 1315
  • [9] SEQUENTIAL INTERLEUKIN-2 AND ALPHA-INTERFERON FOR RENAL-CELL CARCINOMA AND MELANOMA
    THOMAS, H
    BARTON, C
    SAINI, A
    DALGLEISH, A
    WAXMAN, J
    EUROPEAN JOURNAL OF CANCER, 1992, 28A (6-7) : 1047 - 1049
  • [10] SUBCUTANEOUS RECOMBINANT INTERLEUKIN-2 AND ALPHA-INTERFERON IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA - RESULTS OF A MULTICENTER PHASE-II STUDY
    ATZPODIEN, J
    KIRCHNER, H
    DEMULDER, P
    BODENSTEIN, H
    OLIVER, T
    PALMER, PA
    FRANKS, CR
    POLIWODA, H
    CANCER BIOTHERAPY, 1993, 8 (04): : 289 - 300